Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
corticosteroid therapy · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| inhaled corticosteroid therapy | DRUG | - |
Inclusion Criteria: * Male and/or female moderate to severe asthmatic patients, from 18-75 years of age. * Moderate to severe asthma, according to the GINA guidelines, for at least one year with no exacerbations requiring hospitalization and/or oral steroids within the previous three months. * No c...
Corticosteroid therapy is an investigational small molecule being studied for the treatment of moderate to severe bronchial asthma. It is administered via inhalation and is currently in Phase 1 clinical development. The therapy is being evaluated for its efficacy in managing asthma symptoms in adult patients.
Corticosteroid therapy works by reducing inflammation in the airways, which is a key component of asthma pathophysiology. As a corticosteroid, it is designed to modulate the inflammatory response that contributes to bronchial constriction and asthma symptoms. This mechanism is being investigated in the context of moderate to severe bronchial asthma.
Corticosteroid therapy is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol NVS. Novartis is conducting clinical research to evaluate the safety and efficacy of this inhaled corticosteroid for the treatment of bronchial asthma.
Corticosteroid therapy is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the therapy is being evaluated for its efficacy in patients with moderate to severe bronchial asthma.
Corticosteroid therapy has been studied in one clinical trial, identified as NCT00411567, titled 'A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma.' This Phase 1 trial was completed in Germany and enrolled 26 adult participants with bronchial asthma.
Corticosteroid therapy is an inhaled corticosteroid (ICS) therapy, as indicated by the clinical trial title. The drug is administered via inhalation and is being studied for its efficacy in treating moderate to severe bronchial asthma. The trial specifically evaluates the efficacy of this inhaled corticosteroid formulation.